Denali Therapeutics Inc. (DNLI): Price and Financial Metrics
Denali Therapeutics Inc. (DNLI)
Today's Latest Price: $41.14 USD
Updated Oct 23 4:00pm
Add DNLI to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
DNLI Stock Summary
- DNLI's price/sales ratio is 151.6; that's higher than the P/S ratio of 97.82% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, Denali Therapeutics Inc is reporting a growth rate of 289.15%; that's higher than 95.12% of US stocks.
- As for revenue growth, note that DNLI's revenue has grown -79.5% over the past 12 months; that beats the revenue growth of just 1.81% of US companies in our set.
- Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are PRQR, ARGX, FATE, NKTR, and XNCR.
- DNLI's SEC filings can be seen here. And to visit Denali Therapeutics Inc's official web site, go to www.denalitherapeutics.com.
DNLI Stock Price Chart Interactive Chart >
DNLI Price/Volume Stats
| Current price | $41.14 | 52-week high | $45.82 |
| Prev. close | $40.92 | 52-week low | $12.39 |
| Day low | $39.09 | Volume | 360,700 |
| Day high | $41.37 | Avg. volume | 640,516 |
| 50-day MA | $36.17 | Dividend yield | N/A |
| 200-day MA | $26.46 | Market Cap | 4.36B |
Denali Therapeutics Inc. (DNLI) Company Bio
Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.
Loading social stream, please wait...